Plus   Neg

Cognizant To Buy Privately-held Zenith Technologies, Terms Not Disclosed

Cognizant Technology Solutions Corp. (CTSH) announced Tuesday that it has agreed to acquire Zenith Technologies, an Irish privately-held life sciences manufacturing technology services company. Financial details were not disclosed.

The acquisition is expected to close in the third quarter of 2019, subject to satisfaction of closing conditions, including regulatory review.

Following the transaction, Zenith Technologies' more than 800 people will become part of Cognizant's Life Sciences business unit.

Founded in 1998, Zenith Technologies specializes in implementing digital technologies to manage, control and optimize drug and medical device production. It operates on five continents, with 16 locations globally.

Brian Humphries, Chief Executive Officer, Cognizant said, "Industry 4.0 solutions, encompassing Internet of Things (IoT), automation and analytics, are a strategic focus area for Cognizant. In acquiring Zenith Technologies, we expand Cognizant's IoT portfolio and extend our life sciences domain expertise by becoming a single-source provider of end-to-end smart factory capabilities."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
Follow RTT